In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Wave Life Sciences, with a price target of $22.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andrew Fein has given his Buy rating due to a combination of factors that highlight the promising potential of Wave Life Sciences’ WVE-007. The recent data from the INLIGHT readout for WVE-007 demonstrated a notable differentiation in the obesity treatment landscape, particularly with its ability to reduce visceral fat by 9.2% while simultaneously increasing lean mass by 0.9%. This outcome supports the company’s “Quality of Weight Loss” thesis, distinguishing it from other treatments like GLP-1s that may lead to muscle loss.
Furthermore, the durability of the treatment, with 75-78% Activin E silencing maintained through Day 85, suggests the feasibility of a less frequent dosing regimen, which is a significant validation for the RNA silencing platform. The successful human translation of the GalNAc-siRNA chemistry also mitigates delivery risks, bolstering confidence in the platform’s potential. These factors, combined with existing collaborations and a robust pipeline, underpin the optimistic outlook for Wave Life Sciences, justifying the Buy rating.
In another report released today, Jefferies also maintained a Buy rating on the stock with a $26.00 price target.